Global Danoprevir Sodium Market Strategic Research Report

Scope of the Report

The global Danoprevir Sodium market size is predicted to grow from US$ 1,761 million in 2025 to US$ 230 million in 2032; it is expected to grow at a CAGR of 19.7% from 2026 to 2032.

In 2025, global Danoprevir Sodium production reached approximately 23,000 units.Danoprevir Sodium (brand name: Ganovo), independently developed by Ascletis Pharma, is China’s first domestically originated Class 1 chemical anti‑hepatitis C virus (HCV) drug. Classified as a new‑generation NS3/4A protease inhibitor among direct‑acting antivirals (DAAs), it is an achievement of the national Major New Drug Creation Project. Approved by the NMPA in June 2018, it is indicated for the targeted antiviral treatment of chronic hepatitis C.

Danoprevir Sodium is an NS3/4A protease inhibitor targeting hepatitis C virus (HCV), typically used in combination with other direct-acting antivirals (DAAs), and has an established application base in China’s HCV antiviral treatment market. With the continued advancement of the national “hepatitis C elimination” strategy and improvements in screening and diagnosis rates, treatment demand is being progressively released, providing a stable market opportunity for this drug.

From a competitive landscape perspective, pan-genotypic DAA regimens centered on Sofosbuvir, along with imported originator products, still dominate the market. However, danoprevir sodium, leveraging its domestic R&D background, pricing advantages, and value in specific combination regimens, demonstrates a certain level of competitiveness in selected patient populations.

On the policy side, national reimbursement negotiations and volume-based procurement continue to drive down drug prices, while significantly improving treatment accessibility and accelerating market uptake. From a competitive standpoint, the launch of multiple new DAA combination regimens is intensifying market competition. Therefore, the future market performance of danoprevir sodium will depend on its clinical positioning within combination therapies, the accumulation of real-world efficacy and safety data, and its overall competitiveness in pricing, distribution channels, and reimbursement coverage.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Danoprevir Sodium market?

What factors are driving Danoprevir Sodium market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Danoprevir Sodium market opportunities vary by end market size?

How does Danoprevir Sodium break out by Type, by Application?

This report presents a comprehensive overview of the global Danoprevir Sodium market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100 mg/tablet
• 200 mg/tablet

Segment by Dosage form

• Tablet
• Capsule

Segment by Release type

• Immediate-release (IR)
• Sustained-release (SR)

Segment by Application

• Treatment-naïve Adult Patients With Chronic hepatitis C
• Non-cirrhotic Population
• Confirmed HCV Genotype 1b Infection
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Danoprevir Sodium market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Treatment-naïve Adult Patients With Chronic hepatitis C, Non-cirrhotic Population, Confirmed HCV Genotype 1b Infection evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact